Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Eric L,Simpson

第一单位： Department of Dermatology, Oregon Health & Science University, Portland, Oregon.

作者： Eric L,Simpson ^[1] ; Jonathan I,Silverberg ^[2] ; Margitta,Worm ^[3] ; Golara,Honari ^[4] ; Koji,Masuda ^[5] ; Ewa,Syguła ^[6] ; Marie L A,Schuttelaar ^[7] ; Eric,Mortensen ^[8] ; Elizabeth,Laws ^[9] ; Bolanle,Akinlade ^[8] ; Naimish,Patel ^[10] ; Jennifer,Maloney ^[8] ; Heather,Paleczny ^[8] ; Dimittri,Delevry ^[8] ; Jing,Xiao ^[8] ; Ariane,Dubost-Brama ^[11] ; Ashish,Bansal ^[12]

作者单位： Department of Dermatology, Oregon Health & Science University, Portland, Oregon. ^[1] The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia. ^[2] Division of Allergy and Immunology, Department Dermatology, Venerology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany. ^[3] Department of Dermatology, Stanford University School of Medicine, Stanford, California. ^[4] Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan. ^[5] Department of Dermatology, Andrzej Mielȩcki Memorial Independent Public Clinical Hospital, Katowice, Poland. ^[6] Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. ^[7] Regeneron Pharmaceuticals Inc, Tarrytown, New York. ^[8] Sanofi, Bridgewater, New Jersey. ^[9] Sanofi, Cambridge, Massachusetts. ^[10] Sanofi, Chilly-Mazarin, France. ^[11] Regeneron Pharmaceuticals Inc, Tarrytown, New York. Electronic address: ashish.bansal@regeneron.com. ^[12]

关键词 atopic hand and foot dermatitis dupilumab hand eczema interleukin-13 interleukin-4 pruritus,?type 2 inflammation